Key Highlights

  • The first quarter of fiscal 2027, which closed August 31, 2026, brought in USD 257.1 million of net revenue, up 23% from USD 209.5 million, according to figures released October 8, 2026.
  • A net loss of USD 40.0 million, or USD 0.32 a share, came mostly from non-cash charges, and adjusted EBITDA stood at USD 9.2 million compared with USD 10.2 million the prior year.
  • Liquidity across cash, restricted cash and marketable securities reached USD 221.4 million, USD 42 million of Debt has been retired so far this fiscal year, and management described the quarter-end position as net cash.
  • A USD 2.94 price, up 10.74% on 4.513 million shares, appeared in undated market data that has not been verified.

Revenue Expansion Against a Heavy Net Loss

Tilray Brands (NASDAQ:TLRY) lifted Gross Profit 35% to USD 77.5 million, and gross Margin moved up to 30% from 27%. The beverage line jumped 82% to USD 101.5 million because of the BrewDog acquisition, and BrewDog became profitable during the period. Cannabis revenue, meanwhile, slid to USD 56.1 million from USD 64.5 million, though the cannabis gross margin improved to 39%. Distribution sales advanced 14% to USD 84.3 million, while wellness stayed level at USD 15.3 million. These numbers come from an 8-K exhibit filed on October 8, 2026.

Reaffirmed Guidance, Carlsberg and the Reverse Split Background

Leadership restated its fiscal 2027 adjusted EBITDA aim of USD 68 million to USD 75 million and observed that profits tend to be concentrated in the back half. Against that aim, the first quarter's USD 9.2 million amounts to roughly 12% to 14%, a rough calculation. Brewing and sales of Carlsberg products in the American market are slated to commence on January 1, 2027. Restructuring costs reached USD 2.4 million, and Transaction Costs USD 4.8 million. A filing headline points to a 1-for-10 reverse split executed in late November 2025, which means the per-share figures are on a post-split basis.

Penny Stock Risk Following a 10.74% Move

Priced at USD 2.94 on the quotes cited, Tilray sits in Penny Stock territory, where a handful of orders can change the price, spreads can be broad and gains can unwind. A low share price does not shrink operating risk. Cannabis sales are shrinking, the net loss is sizable and the guidance relies on a stronger second half. The 10.74% move has no confirmed cause and should not be treated as a trend. Net debt, cash and the cannabis trend are the figures to watch, and because management describes a quarterly pattern, the first half may appear weaker than the full year.

Where Things Stand

The 10.74% increase does not clearly follow from the quarter, because a USD 40.0 million loss and falling cannabis Revenue are not positives. Tilray did deliver higher sales, a better gross margin, a net cash position and reaffirmed targets, which may explain some interest, but no single cause can be pinned to the move. Unverified, undated quote data cannot settle the question. Restructuring and transaction costs of USD 7.2 million combined, a simple sum, made up a small part of the loss. Second-quarter figures, the Carlsberg launch slated for January 1, 2027, the direction of cannabis sales and how close the company gets to its USD 68 million to USD 75 million EBITDA goal all bear watching.